Immune to Cancer: The CRI Blog
-
ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV
The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…
-
Dr. Robert Schreiber and Interferon Gamma
By redefining our understanding of the relationship between cancer and the immune system, Dr. Robert Schreiber has…
-
AACR19 Day 3 Update: CAR T Cells, Vaccines, and Hope Against Pancreatic Cancer
In addition to advances involving CAR T cell therapy and vaccines, a CRI-funded trial revealed the promise…
-
CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…
-
Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer
Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.
-
How Immunotherapy Is Making an Impact in Liver Cancer
We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…